Today: October 6, 2015, 4:51 pm

Latvia pharmaceutical market: Latest market research analysed
The Pharmaceutical Market: Latvia - a new market research report on 2014-03-13 14:55:01
Our view of the Latvian pharmaceutical market remains shaped by the prevailing economic conditions given the high out-of-pocket contributions to medicine spending . This is especially pertinent as the government has over the recent months cut healthcare spending in a bid to remain eligible for EU and IMF loan packages, as well in preparation for potential eurozone membership . While we still expect the market to contract in US dollar terms in 2012, the contraction is expected to be less severe, at 2.4% on a year-on-year basis on account of a somewhat improved economic environment and stronger-than-expected wholesale trade .

Headline Expenditure Projections

Pharmaceuticals: LVL206mn (US$405mn) in 2011 to LVL220mn (US$396mn) in 2012; +7.0% in local currency terms and -2.4% in US dollar terms. Forecast up from Q412 on account of improved macroeconomic and wholesale trade data.

Healthcare: LVL893mn (US$1.76bn) in 2011 to LVL926mn (US$1.66bn) in 2012; +3.7% in local currency terms and -5.4% in US dollar terms. Forecast unchanged from Q 4 12.

Medical Devices: LVL78mn (US$153mn) in 2011 to LVL81mn (US$145mn) in 2012; +3.7% in local currency terms and -5.4% in US dollar terms. Forecast unchanged from Q 4 12.

Risk/Reward Rating

While Latvia offers a favourable risk profile, supported by a business-friendly operating environment, its pharmaceutical market value is expected to shrink in 2012 as measured in US dollars, which negatively impacts its potential commercial rewards. Therefore, Latvia continues to be viewed as one of the least promising markets in the Emerging Europe region, currently ranking 13th out of the 20 countries surveyed in Q113.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 490 Words
Related Articles
More From Finance
Credit-Yogi Teaches Consumers How To Use HAMP [..]
Be Prepared to Utilize HAMP Lenders do not like to help borrowers prevent foreclosure by accessing the Obama loan modification [..]
Credit-Yogi Informs Military Members Facing Auto Repossession [..]
No one wants to have their vehicle taken back by their banks. It’s a source of stress for the individual [..]
Credit-Yogi .com Teaches Consumers How To Prevent [..]
Want to Halt Vehicle Repossession? Here’s How Sometimes things happen that end up leaving one in a financially strapped position. [..]
Sell Your Phoenix Winter Condo or Townhouse [..]
Most condominium owners or homeowners, in almost every state in the country, are asking the same question: “Should I sell [..] Shows Homeowners How To Avoid Foreclosure [..]
The idea that someone could lose his home to his lender is just scary, and he may not know how [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.